Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
NEW YORK, Aug. 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) between January 14, 2016 and July 26, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Shanawaz v. Intellipharmaceutics International Inc., et al. (Case No. 1:17-cv-05761) in the USDC for the Southern District of New York. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra-sbm/intellipharmaceutics-international-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) the Company did not include abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of the drug by various pathways; (3) the Company was not submitting sufficient data to support approval of the NDA; and (4) as a result, Defendants’ statements about Intellipharmaceutics’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
On July 27, 2017, shares of Intellipharmaceutics fell when the FDA released a report disclosing that “The safety information collected in the pharmacokinetic studies was of limited value…”
If you suffered a loss in Intellipharmaceutics you have until September 29, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
